Patients aged @-@ years with NF@-related PNs and imaging evidence of tumor progression were randomized in a double-blinded fashion to receive tipifarnib ( @ mg/m ( @ ) orally every @ h ) or placebo ( phase A ) and crossed over to the opposite treatment arm at the time of tumor progression ( phase B ) .